Literature DB >> 1551633

Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus.

C Housset1, S Pol, F Carnot, F Dubois, B Nalpas, B Housset, P Berthelot, C Brechot.   

Abstract

To evaluate the factors determining the severity of chronic hepatitis B virus infection and the interactions of human immunodeficiency virus and hepatitis delta virus infections, we retrospectively analyzed 260 patients, 146 of whom were followed for a mean of 31.4 +/- 1.8 mo. Human immunodeficiency virus, hepatitis B virus, and hepatitis delta virus status and aminotransferase activities, histological activity index, alcohol consumption and the prevalence of cirrhosis were investigated. The patients included 54 homosexuals, 19 parenteral drug abusers and 187 subjects with other or unidentified risk factors for exposure to hepatitis B virus. Thirty-five patients (13%) were positive for antibody to human immunodeficiency virus; 27 were homosexual and 8 were drug abusers. The mean aminotransferase activities, histological activity index and the prevalence of cirrhosis were similar in the human immunodeficiency virus-positive and human immunodeficiency virus-negative subgroups. Actuarial survival was significantly lower in the human immunodeficiency virus-negative subgroups. Actuarial survival was significantly lower in the human immunodeficiency virus-positive group than in the human immunodeficiency virus-negative subjects (p = 0.004); the cause of death was clearly related to liver failure in four of the five human immunodeficiency virus-positive patients and two of the six human immunodeficiency virus-negative subjects who died. To evaluate the factors determining the severity of liver disease, we compared homogeneous subgroups of subjects. Among the homosexual patients, the prevalence of HBeAg and hepatitis B virus DNA, aminotransferase activities and the histological activity index did not differ according to human immunodeficiency virus antibody status.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551633     DOI: 10.1002/hep.1840150404

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  HIV coinfection with hepatitis C and hepatitis B.

Authors:  Jenny O Smith; Richard K Sterling
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

2.  Molecular epidemiology of hepatitis D virus infection among injecting drug users with and without human immunodeficiency virus infection in Taiwan.

Authors:  Sui-Yuan Chang; Chia-Ling Yang; Wei-Shin Ko; Wen-Chun Liu; Chi-Ying Lin; Cheng-Hsin Wu; Yi-Chin Su; Shu-Fang Chang; Mao-Yuan Chen; Wang-Huei Sheng; Chien-Ching Hung; Shan-Chwen Chang
Journal:  J Clin Microbiol       Date:  2010-12-29       Impact factor: 5.948

Review 3.  Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.

Authors:  M Barry; S Gibbons; D Back; F Mulcahy
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

4.  Hepatitis B virus-human immunodeficiency virus co-infection in France: a cross-sectional multicentre study.

Authors:  D Sène; S Pol; L Piroth; C Goujard; P Dellamonica; J Moussali; D Rey; V Loustaud-Ratti; L Alric; M Chousterman; F Borsa-Lebas; O Boucher; D Séréni; P Cacoub
Journal:  Epidemiol Infect       Date:  2006-07-25       Impact factor: 2.451

Review 5.  Management of hepatitis B in patients coinfected with the human immunodeficiency virus.

Authors:  R Lessells; C Leen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

6.  Sustained elimination of hepatitis B virus from serum induced in a patient with chronic hepatitis B and advanced human immunodeficiency virus infection.

Authors:  T Wölfel; P Schirmacher; J Schlaak; P Knolle; H P Dienes; W Dippold; K H Meyer zum Büschenfelde; G Gerken
Journal:  Clin Investig       Date:  1994-12

7.  High prevalence of hepatitis delta virus among patients with chronic hepatitis B virus infection and HIV-1 in an intermediate hepatitis B virus endemic region.

Authors:  Shanmugam Saravanan; Vidya Madhavan; Vijayakumar Velu; Kailapuri G Murugavel; Greer Waldrop; Sunil S Solomon; Pachamuthu Balakrishnan; Nagalingeswaran Kumarasamy; Davey M Smith; Kenneth H Mayer; Suniti Solomon; Sadras P Thyagarajan
Journal:  J Int Assoc Provid AIDS Care       Date:  2013-05-30

8.  HIV and Hepatitis Virus Infection.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.663

9.  Occult hepatitis B virus infection: A major concern in HIV-infected patients: Occult HBV in HIV.

Authors:  Amitis Ramezani; Mohammad Banifazl; Minoo Mohraz; Mehrnaz Rasoolinejad; Arezoo Aghakhani
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.